Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drug Discovery company C4X Discovery reported narrower annual losses as its €414 million agreement with Sanofi bolstered results.
For the year ended 31 July 2021, pre-tax losses narrowed to £5.9 million from £9.6 million year-on-year, with revenue of £5.6 million.
The revenue recognised in the current year was part of the €7 million upfront payment from Sanofi on the signing of the IL-17A licence agreement.
'Following the €414 million agreement with Sanofi for our IL-17A oral Inhibitor programme, C4XD is focused on driving forward its portfolio towards future out-licensing opportunities, including NRF-2 where there is significant partnering interest,' it added.